SCHEMBL6774582

SCHEMBL6774582

NN=CNc1cc(C(=O)NCC(=O)NC(CC(=O)O)c2cc(Cl)cc(Cl)c2)ccc1Cl

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 10/20 0.43
ITGAV P06756 9/20 0.43
GPR139 Q6DWJ6 5/20 0.43
ITGB6 P18564 8/20 0.42
ITGB1 P05556 6/20 0.42
ITGA5 P08648 6/20 0.42
ITGB5 P18084 6/20 0.42
ITGB8 P26012 6/20 0.42
ITGA8 P53708 6/20 0.42
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
ITGA2B P08514 1/20 0.40
SLC6A9 P48067 2/20 0.39
SLC6A5 Q9Y345 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ATM Q13315 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL612700 0.85 ITGB3 (0.49) ITGB3ITGAVGPR139ITGB6ITGB1
SCHEMBL6774572 0.85 ITGB3 (0.47) ITGB3ITGAVGPR139ITGB6ITGB1
SCHEMBL7343367 0.84 ITGB3 (0.46) ITGB3ITGAVGPR139ITGB6ITGB1
SCHEMBL6778094 0.82 ITGB3 (0.45) ITGB3ITGAVGPR139ITGB6ITGB1
SCHEMBL6773621 0.81 ITGB3 (0.45) ITGB3ITGAVGPR139ITGB6ITGB1
SCHEMBL7832543 0.79 ITGB3 (0.52) ITGB3ITGAVGPR139ITGB6ITGB1
SCHEMBL6778050 0.79 GPR139 (0.39) GPR139
SCHEMBL6779369 0.79 ITGB3 (0.39) ITGB3ITGAVGPR139ITGB6ITGB1
SCHEMBL7341209 0.79 GPR139 (0.52) ITGB3ITGAVGPR139ITGB6ITGB1
SCHEMBL7832106 0.78 ITGB3 (0.52) ITGB3ITGAVGPR139ITGB6ITGB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP claimed
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed